Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
Date:9/29/2008

SAN DIEGO, Sept. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview on Monday, October 6 at 1:30pm Eastern Time (10:30am Pacific Time) during the JMP Securities Third Annual Healthcare Focus Conference at the Le Parker Meridien Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in- licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter- related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue Anna Gralinska

SVP & Chief Financ
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
4. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
5. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
7. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
8. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 Lawrence Livermore ... to Thomson Reuters list of " The World's Most ... part of the 3,000 researchers who were identified by ... recognize those who published the highest-impact work (2002-2012 and ... papers on combustion modeling . , "This recognition ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, ... Colorado with University College Hospital (UCH) Ibadan ... development project to finance, design, construct, and operate and ... Nigeria . Under the first of the ... scoping documents and funding applications. UCH Ibadan intends to ...
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2
... COPENHAGEN and OSLO, September 1 Affitech ... announced that it,has appointed two experienced biotech executives ... CEO of Celldex Therapeutics Inc., has today,assumed overall ... Dr Alexander Duncan, previously SVP Biopharmaceuticals for Astra,Zeneca ...
... CITY, Sept. 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on endocrine therapy and oncology, ... Medical Officer, Paul Blake, M.D., will present a corporate ... Global Investment Conference on Wednesday, September 9, 2009 at ...
... ... stem cell research and manufacturing, announced today that it has been granted a license ... human clinical trials. This Drug Manufacturing License recognizes Stemedica as being compliant with ... , ...
Cached Biology Technology:Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 3Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 2Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 3
(Date:7/24/2014)... study has identified two factors that characterize sustainable ... production of highly qualified physics teachers. Specifically, one ... physics teacher education in combination with institutional motivation ... viable. Science, Technology, Engineering and Math (STEM) teacher ... study points the way for institutions seeking to ...
(Date:7/24/2014)... June 24, 2014 Some sticky research out of ... against a certain species of toxic grass fungus: moose ... month,s Biology Letters , "Ungulate saliva inhibits a ... applied to red fescue grass (which hosts a fungus ... in slower fungus growth and less toxicity. , "Plants ...
(Date:7/24/2014)... 24, 2014(BRONX, NY)Researchers at Albert Einstein College of ... from The Michael J. Fox Foundation for Parkinson,s Research ... for Parkinson,s disease. This drug discovery project will test ... goal of developing a drug that acts on an ... therapies for Parkinson,s help many people manage their symptoms, ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... The deposition of amyloid beta in the brain of ... into both its cause and treatment. While there ... contributes to the disease or is a consequence of the ... meaning that something else is promoting the process. Other ...
... Have you ever been disappointed by a cantaloupe from the ... researchers from the University of California, Davis might have found ... the past. The method will be published on March 30 ... ). "We are involved in a project geared towards ...
... if there is a link between living near nuclear power ... of cancer, but challenges and limitations exist, says a new ... the National Academy of Sciences and National Academy of Engineering. ... first to evaluate the feasibility of a full-scale study, although ...
Cached Biology News:The electronic nose knows when your cantaloupe is ripe 2Report presents designs for study of cancer risks near US nuclear facilities 2Report presents designs for study of cancer risks near US nuclear facilities 3
... Clarin represents the state-of-the-art in ... for the permanent preservation of immunohistochemical ... (DAB), Vega Red, New Fuchsin, and ... substrates on tissue sections. Clarin can ...
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
... ProLink Express is the first fully automated ... and transfer operations with complete data tracking. ... bacterial colony picking through final protein expression ... capable of delivering a plate to any ...
... multi-functional program that searches for ... sequence file for polymerase chain ... mutagenesis, and various hybridization applications. ... secondary structure of oligonucleotides based ...
Biology Products: